Global Urological Cancer Therapeutics Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 05-Oct-2022
No. of pages: 129
Inquire Before Buying

Report Scope

This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Urological Cancer Therapeutics Drugs manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Urological Cancer Therapeutics Drugs market. Further, it explains the major drivers and regional dynamics of the global Urological Cancer Therapeutics Drugs market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Novartis

- Pfizer

- Johnson & Johnson

- AstraZeneca

- Astellas

- Bristol-Myers Squibb

- Abbott Laboratories

- Celgene Corporation

- Dendreon Corporation

- Ferring Pharmaceuticals

- GlaxoSmithKline plc

- Indevus Pharmaceuticals Inc

- Ipsen

- Roche Healthcare

- Sanofi S.A.

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.

Urological Cancer Therapeutics Drugs Segment by Type

- Xofigo (radium Ra 223 dichloride)

- Jevtana (cabazitaxel)

- Inlyta (axitinib)

- Votrient (pazopanib hydrochloride)

- Sutent (sunitinib malate)

- Zytiga (abiraterone acetate)

- Xtandi (enzalutamide)

- Opdivo (nivolumab)

- Provenge (sipuleucel-T)

Urological Cancer Therapeutics Drugs Segment by Application

- Hospital

- Medical Research Laboratory

- Others

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - China Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Urological Cancer Therapeutics Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Urological Cancer Therapeutics Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Urological Cancer Therapeutics Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Urological Cancer Therapeutics Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Urological Cancer Therapeutics Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Urological Cancer Therapeutics Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Urological Cancer Therapeutics Drugs sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc.

Global Urological Cancer Therapeutics Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Xofigo (radium Ra 223 dichloride)
1.2.3 Jevtana (cabazitaxel)
1.2.4 Inlyta (axitinib)
1.2.5 Votrient (pazopanib hydrochloride)
1.2.6 Sutent (sunitinib malate)
1.2.7 Zytiga (abiraterone acetate)
1.2.8 Xtandi (enzalutamide)
1.2.9 Opdivo (nivolumab)
1.2.10 Provenge (sipuleucel-T)
1.3 Market Segment by Application
1.3.1 Global Urological Cancer Therapeutics Drugs Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Urological Cancer Therapeutics Drugs Market Size (2017-2028)
2.1.1 Global Urological Cancer Therapeutics Drugs Revenue (2017-2028)
2.1.2 Global Urological Cancer Therapeutics Drugs Sales (2017-2028)
2.2 Global Urological Cancer Therapeutics Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Urological Cancer Therapeutics Drugs Sales by Regions (2017-2022)
2.2.2 Global Urological Cancer Therapeutics Drugs Revenue by Regions (2017-2022)
2.3 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Region
2.3.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2023-2028)
2.3.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2023-2028)
2.4 Global Top Urological Cancer Therapeutics Drugs Regions (Countries) Ranking by Market Size
2.5 Urological Cancer Therapeutics Drugs Market Dynamics
2.5.1 Urological Cancer Therapeutics Drugs Market Trends
2.5.2 Urological Cancer Therapeutics Drugs Market Drivers
2.5.3 Urological Cancer Therapeutics Drugs Market Challenges
2.5.4 Urological Cancer Therapeutics Drugs Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Urological Cancer Therapeutics Drugs Manufacturers by Sales (2017-2022)
3.1.1 Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2017-2022)
3.1.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Urological Cancer Therapeutics Drugs Sales in 2021
3.2 Global Top Manufacturers Urological Cancer Therapeutics Drugs by Revenue
3.2.1 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Top Urological Cancer Therapeutics Drugs Manufacturers Covered: Ranking by Revenue
3.2.3 Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2021)
3.4 Global Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Urological Cancer Therapeutics Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
3.7 Key Manufacturers Urological Cancer Therapeutics Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Urological Cancer Therapeutics Drugs Market Size by Type
4.1 Global Urological Cancer Therapeutics Drugs Historic Market Review by Type (2017-2022)
4.1.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
4.1.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2017-2022)
4.1.3 Urological Cancer Therapeutics Drugs Price by Type (2017-2022)
4.2 Global Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2023-2028)
4.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2023-2028)
4.2.3 Urological Cancer Therapeutics Drugs Price Forecast by Type (2023-2028)
5 Global Urological Cancer Therapeutics Drugs Market Size by Application
5.1 Global Urological Cancer Therapeutics Drugs Historic Market Review by Application (2017-2022)
5.1.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
5.1.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2017-2022)
5.1.3 Urological Cancer Therapeutics Drugs Price by Application (2017-2022)
5.2 Global Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2023-2028)
5.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2023-2028)
5.2.3 Urological Cancer Therapeutics Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Urological Cancer Therapeutics Drugs Sales Breakdown by Company
6.1.1 North America Urological Cancer Therapeutics Drugs Sales by Company (2017-2022)
6.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022)
6.2 North America Urological Cancer Therapeutics Drugs Market Size by Type
6.2.1 North America Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
6.2.2 North America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
6.3 North America Urological Cancer Therapeutics Drugs Market Size by Application
6.3.1 North America Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
6.3.2 North America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
6.4 North America Urological Cancer Therapeutics Drugs Market Size by Country
6.4.1 North America Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
6.4.2 North America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Urological Cancer Therapeutics Drugs Sales Breakdown by Company
7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Company (2017-2022)
7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022)
7.2 Europe Urological Cancer Therapeutics Drugs Market Size by Type
7.2.1 Europe Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
7.2.2 Europe Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
7.3 Europe Urological Cancer Therapeutics Drugs Market Size by Application
7.3.1 Europe Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
7.3.2 Europe Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
7.4 Europe Urological Cancer Therapeutics Drugs Market Size by Country
7.4.1 Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
7.4.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales Breakdown by Company
8.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Company (2017-2022)
8.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022)
8.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Size by Type
8.2.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
8.2.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
8.3 Asia Pacific Urological Cancer Therapeutics Drugs Market Size by Application
8.3.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
8.3.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
8.4 Asia Pacific Urological Cancer Therapeutics Drugs Market Size by Region
8.4.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
8.4.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 China Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
9 Latin America
9.1 Latin America Urological Cancer Therapeutics Drugs Sales Breakdown by Company
9.1.1 Latin America Urological Cancer Therapeutics Drugs Sales by Company (2017-2022)
9.1.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022)
9.2 Latin America Urological Cancer Therapeutics Drugs Market Size by Type
9.2.1 Latin America Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
9.2.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
9.3 Latin America Urological Cancer Therapeutics Drugs Market Size by Application
9.3.1 Latin America Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
9.3.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
9.4 Latin America Urological Cancer Therapeutics Drugs Market Size by Country
9.4.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
9.4.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales Breakdown by Company
10.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Company (2017-2022)
10.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022)
10.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size by Type
10.2.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
10.2.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
10.3 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size by Application
10.3.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
10.3.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
10.4 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size by Country
10.4.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
10.4.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Overview
11.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Novartis Urological Cancer Therapeutics Drugs Products and Services
11.1.5 Novartis Urological Cancer Therapeutics Drugs SWOT Analysis
11.1.6 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 Pfizer Urological Cancer Therapeutics Drugs Products and Services
11.2.5 Pfizer Urological Cancer Therapeutics Drugs SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Overview
11.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products and Services
11.3.5 Johnson & Johnson Urological Cancer Therapeutics Drugs SWOT Analysis
11.3.6 Johnson & Johnson Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products and Services
11.4.5 AstraZeneca Urological Cancer Therapeutics Drugs SWOT Analysis
11.4.6 AstraZeneca Recent Developments
11.5 Astellas
11.5.1 Astellas Corporation Information
11.5.2 Astellas Overview
11.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Astellas Urological Cancer Therapeutics Drugs Products and Services
11.5.5 Astellas Urological Cancer Therapeutics Drugs SWOT Analysis
11.5.6 Astellas Recent Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Corporation Information
11.6.2 Bristol-Myers Squibb Overview
11.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products and Services
11.6.5 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs SWOT Analysis
11.6.6 Bristol-Myers Squibb Recent Developments
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Corporation Information
11.7.2 Abbott Laboratories Overview
11.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products and Services
11.7.5 Abbott Laboratories Urological Cancer Therapeutics Drugs SWOT Analysis
11.7.6 Abbott Laboratories Recent Developments
11.8 Celgene Corporation
11.8.1 Celgene Corporation Corporation Information
11.8.2 Celgene Corporation Overview
11.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products and Services
11.8.5 Celgene Corporation Urological Cancer Therapeutics Drugs SWOT Analysis
11.8.6 Celgene Corporation Recent Developments
11.9 Dendreon Corporation
11.9.1 Dendreon Corporation Corporation Information
11.9.2 Dendreon Corporation Overview
11.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products and Services
11.9.5 Dendreon Corporation Urological Cancer Therapeutics Drugs SWOT Analysis
11.9.6 Dendreon Corporation Recent Developments
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Corporation Information
11.10.2 Ferring Pharmaceuticals Overview
11.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products and Services
11.10.5 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs SWOT Analysis
11.10.6 Ferring Pharmaceuticals Recent Developments
11.11 GlaxoSmithKline plc
11.11.1 GlaxoSmithKline plc Corporation Information
11.11.2 GlaxoSmithKline plc Overview
11.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products and Services
11.11.5 GlaxoSmithKline plc Recent Developments
11.12 Indevus Pharmaceuticals Inc
11.12.1 Indevus Pharmaceuticals Inc Corporation Information
11.12.2 Indevus Pharmaceuticals Inc Overview
11.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Products and Services
11.12.5 Indevus Pharmaceuticals Inc Recent Developments
11.13 Ipsen
11.13.1 Ipsen Corporation Information
11.13.2 Ipsen Overview
11.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 Ipsen Urological Cancer Therapeutics Drugs Products and Services
11.13.5 Ipsen Recent Developments
11.14 Roche Healthcare
11.14.1 Roche Healthcare Corporation Information
11.14.2 Roche Healthcare Overview
11.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Products and Services
11.14.5 Roche Healthcare Recent Developments
11.15 Sanofi S.A.
11.15.1 Sanofi S.A. Corporation Information
11.15.2 Sanofi S.A. Overview
11.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Products and Services
11.15.5 Sanofi S.A. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Urological Cancer Therapeutics Drugs Value Chain Analysis
12.2 Urological Cancer Therapeutics Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Urological Cancer Therapeutics Drugs Production Mode & Process
12.4 Urological Cancer Therapeutics Drugs Sales and Marketing
12.4.1 Urological Cancer Therapeutics Drugs Sales Channels
12.4.2 Urological Cancer Therapeutics Drugs Distributors
12.5 Urological Cancer Therapeutics Drugs Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Xofigo (radium Ra 223 dichloride)
Table 3. Major Manufacturers of Jevtana (cabazitaxel)
Table 4. Major Manufacturers of Inlyta (axitinib)
Table 5. Major Manufacturers of Votrient (pazopanib hydrochloride)
Table 6. Major Manufacturers of Sutent (sunitinib malate)
Table 7. Major Manufacturers of Zytiga (abiraterone acetate)
Table 8. Major Manufacturers of Xtandi (enzalutamide)
Table 9. Major Manufacturers of Opdivo (nivolumab)
Table 10. Major Manufacturers of Provenge (sipuleucel-T)
Table 11. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 12. Global Urological Cancer Therapeutics Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 13. Global Urological Cancer Therapeutics Drugs Sales by Region (2017-2022) & (K MT)
Table 14. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2017-2022)
Table 15. Global Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 16. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2017-2022)
Table 17. Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2023-2028) & (K MT)
Table 18. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Region (2023-2028)
Table 19. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 20. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 21. Top Urological Cancer Therapeutics Drugs Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 22. Urological Cancer Therapeutics Drugs Market Trends
Table 23. Urological Cancer Therapeutics Drugs Market Drivers
Table 24. Urological Cancer Therapeutics Drugs Market Challenges
Table 25. Urological Cancer Therapeutics Drugs Market Restraints
Table 26. Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2017-2022) & (K MT)
Table 27. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2017-2022)
Table 28. Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 29. Ranking of Global Top Urological Cancer Therapeutics Drugs Manufacturers by Revenue (US$ Million) in 2021
Table 30. Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2017-2022)
Table 31. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2021)
Table 33. Key Manufacturers Urological Cancer Therapeutics Drugs Average Selling Price (ASP) & (2017-2022) & (USD/MT)
Table 34. Key Manufacturers Urological Cancer Therapeutics Drugs Plants/Factories Distribution
Table 35. Key Manufacturers Urological Cancer Therapeutics Drugs Area Served
Table 36. Date of Key Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
Table 37. Key Manufacturers Urological Cancer Therapeutics Drugs Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2017-2022)
Table 40. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2017-2022)
Table 41. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Type (2017-2022)
Table 42. Global Urological Cancer Therapeutics Drugs Price (K MT) by Type (2017-2022)
Table 43. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2023-2028)
Table 44. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2023-2028)
Table 45. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Type (2023-2028)
Table 46. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2023-2028)
Table 47. Global Urological Cancer Therapeutics Drugs Price (K MT) by Type (2023-2028)
Table 48. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2017-2022)
Table 49. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2017-2022)
Table 50. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Application (2017-2022)
Table 51. Global Urological Cancer Therapeutics Drugs Price (K MT) by Application (2017-2022)
Table 52. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2023-2028)
Table 53. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2023-2028)
Table 54. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Application (2023-2028)
Table 55. Global Urological Cancer Therapeutics Drugs Revenue Share by Application (2023-2028)
Table 56. Global Urological Cancer Therapeutics Drugs Price (K MT) by Application (2023-2028)
Table 57. North America Urological Cancer Therapeutics Drugs Sales by Company (2017-2022) & (K MT)
Table 58. North America Urological Cancer Therapeutics Drugs Sales Market Share by Company (2017-2022)
Table 59. North America Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 60. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2017-2022)
Table 61. North America Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 62. North America Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 63. North America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 64. North America Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 65. North America Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 66. North America Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 67. North America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 68. North America Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 69. North America Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 70. North America Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 71. North America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 72. North America Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 73. Europe Urological Cancer Therapeutics Drugs Sales by Company (2017-2022) & (K MT)
Table 74. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Company (2017-2022)
Table 75. Europe Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 76. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2017-2022)
Table 77. Europe Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 78. Europe Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 79. Europe Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 80. Europe Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 81. Europe Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 82. Europe Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 83. Europe Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 84. Europe Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 85. Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 86. Europe Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 87. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 88. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 89. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Company (2017-2022) & (K MT)
Table 90. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Company (2017-2022)
Table 91. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 92. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2017-2022)
Table 93. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 94. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 95. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 96. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 97. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 98. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 99. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 100. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 101. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2017-2022) & (K MT)
Table 102. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2023-2028) & (K MT)
Table 103. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 104. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 105. Latin America Urological Cancer Therapeutics Drugs Sales by Company (2017-2022) & (K MT)
Table 106. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Company (2017-2022)
Table 107. Latin America Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 108. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2017-2022)
Table 109. Latin America Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 110. Latin America Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 111. Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 112. Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 113. Latin America Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 114. Latin America Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 115. Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 116. Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 117. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 118. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 119. Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 120. Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 121. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Company (2017-2022) & (K MT)
Table 122. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Company (2017-2022)
Table 123. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 124. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2017-2022)
Table 125. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 126. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 127. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 128. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 129. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 130. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 131. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2017-
  • Global Impotence Agents Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 90
    Impotence agents are the type of agents that used to treat erectile dysfunction in males and enable to increase sexual intercourse. These agents generally increase vasodilation and blood flow to the male genital organ and cause an erection. It is becoming of great importance to the healthcare sector and is expected to expand in the coming times. Highlights The global Impotence Agents market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR o......
  • Global CoQ10 Capsule Supplement Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 113
    Highlights The global CoQ10 Capsule Supplement market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for CoQ10 Capsule Supplement is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for CoQ10 Capsule Supplement is estimated to increase from $ million in 2022 to reach $ million ......
  • Global CoQ10 Dietary Supplement Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 112
    Highlights The global CoQ10 Dietary Supplement market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for CoQ10 Dietary Supplement is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for CoQ10 Dietary Supplement is estimated to increase from $ million in 2022 to reach $ million ......
  • Global Intravenous Anticoagulants Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 98
    Anticoagulants are medicines that prevent blood clots from forming and stop existing clots from growing bigger. Highlights The global Intravenous Anticoagulants market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for Intravenous Anticoagulants is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.......
  • Global Obstetrics and Gynecology Drugs Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 99
    Highlights The global Obstetrics and Gynecology Drugs market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 202......
  • Global Huoxiang Zhengqi for COVID-19 Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 97
    Highlights The global Huoxiang Zhengqi for COVID-19 market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for Huoxiang Zhengqi for COVID-19 is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for Huoxiang Zhengqi for COVID-19 is estimated to increase from $ million in 2022 to r......
  • Global Non-Insulin Hypoglycemic Drug Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 101
    Highlights The global Non-Insulin Hypoglycemic Drug market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for Non-Insulin Hypoglycemic Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for Non-Insulin Hypoglycemic Drug is estimated to increase from $ million in 2022 to r......
  • Global Sonidegib Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 69
    It is an oral Hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma who are ineligible for surgery or radiation, or who have relapsed after surgery or radiation. Highlights The global Sonidegib market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for Sonidegib is estimated to increase from $ million in 2022 to reach $ mil......
  • Global Isolate CBD Oil Market Research Report 2022
    Published: 28-Nov-2022        Price: US 2900 Onwards        Pages: 98
    Highlights The global Isolate CBD Oil market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028. North American market for Isolate CBD Oil is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for Isolate CBD Oil is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % dur......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs